000 | 01976 a2200553 4500 | ||
---|---|---|---|
005 | 20250516024515.0 | ||
264 | 0 | _c20110415 | |
008 | 201104s 0 0 eng d | ||
022 | _a1537-6613 | ||
024 | 7 |
_a10.1093/infdis/jiq114 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aFitzgerald, D W | |
245 | 0 | 0 |
_aAn Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). _h[electronic resource] |
260 |
_bThe Journal of infectious diseases _cMar 2011 |
||
300 |
_a765-72 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAIDS Vaccines _ximmunology |
650 | 0 | 4 |
_aAdenoviruses, Human _xgenetics |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAnti-Retroviral Agents _xtherapeutic use |
650 | 0 | 4 | _aBlotting, Western |
650 | 0 | 4 | _aCD4 Lymphocyte Count |
650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _ximmunology |
650 | 0 | 4 | _aCircumcision, Male |
650 | 0 | 4 | _aDisease-Free Survival |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aGenetic Vectors |
650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
650 | 0 | 4 |
_aHIV-1 _xgenetics |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunity, Cellular |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aPlacebos |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 |
_aRNA, Viral _xblood |
650 | 0 | 4 |
_aViral Load _xdrug effects |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aJanes, H | |
700 | 1 | _aRobertson, M | |
700 | 1 | _aCoombs, R | |
700 | 1 | _aFrank, I | |
700 | 1 | _aGilbert, P | |
700 | 1 | _aLoufty, M | |
700 | 1 | _aMehrotra, D | |
700 | 1 | _aDuerr, A | |
773 | 0 |
_tThe Journal of infectious diseases _gvol. 203 _gno. 6 _gp. 765-72 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1093/infdis/jiq114 _zAvailable from publisher's website |
999 |
_c20619180 _d20619180 |